
Valeant appoints new executive VP of finance and CFO
pharmafile | August 22, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Valeant, appointmentÂ
Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief financial officer from Robert L. Rosiello effective immediately. Rosiello will remain at the company in the capacity of executive vice president of corporate development and strategy.
At Valeant, Herendeen will oversee all finance functions including controllership, tax and treasury, reporting directly to CEO Joseph Papa.
“Paul is an accomplished and well respected financial executive, and we are delighted to welcome him to Valeant,” commented Papa. “His prior experience as a public company CFO, strong operational focus and disciplined approach to financial management make him the ideal choice to lead our finance function as we execute on our plans to stabilize and transform the company. As we move forward, Paul and the other members of the executive management team will play vital roles in shaping the new Valeant.”
Boasting over 30 years of financial experience, Herendeen moves to the company from Zoetis where he served as executive vice president and CFO for two years. He has also held roles including 16 years as CFO at Warner Chilcott and MedPointe.
Herendeen himself remarked: “I am pleased to bring my experience and financial expertise to Valeant at this important point in its transformation, and I look forward to working with the leadership team and my finance colleagues to contribute to the company’s future success.”
Matt Fellows
Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …






